tradingview.comNov 10$BTI

Playing defense: British American Tobacco is one of JPMorgan's top picks

JPMorgan analysts highlighted the defensive nature of the European tobacco sector, with British American Tobacco (BTI) as their top pick due to its next-generation product growth and strong share in the U.S. and Europe. Philip Morris (PM) and Imperial Brands (IMBBY) were rated Neutral. The sector is noted for its resilience and shareholder returns.

Original reporting

tradingview.com

Published Nov 10, 2026, 2:57 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 10, 2026, 3:21 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Playing defense: British American Tobacco is one of JPMorgan's top picks — source image — Source · tradingview.com

Decision brief

The 30-second read

$BTIBullishMed

Why it matters

Analyst rating changes can shift investor sentiment and trigger short‑term price moves, especially for BTI.

Market read

The upgrade to Overweight for BTI may drive buying interest, while the neutral stance on PM maintains current positioning.

What to watch

Potential impact of declining traditional cigarette volumes and macro‑economic pressures on margins.

Relevance 7/10Novelty 7/10Timing: today

Background

JPMorgan analysts reviewed the European tobacco sector, emphasizing defensive characteristics and next‑generation product growth.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$BTIBullishHigh confidence

Context

JPMorgan reinstated British American Tobacco to Overweight, citing strong NGP growth and defensive outlook.

Expected impact

likely upward pressure as investors price in the upgraded rating

Evidence & confidence

Overweight rating signals strong earnings potential and defensive positioning, prompting demand.

$PMNeutralHigh confidence

Context

JPMorgan reinstated Philip Morris International to Neutral in its sector coverage.

Expected impact

minimal price movement, market may view as status quo

Evidence & confidence

Neutral rating does not change prior stance, so limited trading impetus.

Market effects

Sector

Highlights defensive appeal of tobacco sector and growth of next‑generation products.

Regional

European tobacco stocks may see broader uplift from the upgrade.

Global

Reinforces tobacco as a safe‑haven within consumer staples globally.

Counterpoint

What could challenge this read

Investors may question the sustainability of growth in NGP amid regulatory scrutiny.

Key entities

company
British American Tobacco
UK‑based tobacco giant, ticker BTI.
company
Philip Morris International
US‑listed tobacco company, ticker PM.

Read at source ← All news

$PMHigh

The U.S. FDA Authorizes ZYN Nicotine Pouches to Be Marketed as Modified Risk Tobacco Products

The FDA authorized 20 ZYN nicotine pouch variants by Philip Morris International (PMI) as Modified Risk Tobacco Products, allowing claims of lower risk of certain diseases compared to cigarettes. The approval is based on PMI's submitted evidence, showing reduced cigarette use among users. The FDA emphasizes these products are not risk-free.

arabtimesonline.comNov 11

$BTIMed

JPMorgan Names Dividend Giant Its Top Stock Pick for a Rocky Market

JPMorgan (JPM) initiated coverage of British American Tobacco (BTI) with an Overweight rating and a 53 price target, citing resilient cash flows, smokeless nicotine growth, and shareholder returns. The bank expects 3-5% revenue growth in 2027 and highlights BTI's defensive characteristics. BTI reported 18% revenue growth in New Categories for H1 2026 and aims for 5-8% EPS growth in 2026.

finance.yahoo.comNov 10

$PMMed

JPMorgan reinstates Philip Morris stock coverage with neutral rating

JPMorgan reinstated Philip Morris (PM) with a Neutral rating and $200 price target, citing leadership in heated tobacco and potential share buybacks. The stock is overvalued per InvestingPro, with a 3.31% dividend yield. PM reported Q3 2026 earnings of $2.36 EPS on $11.4B revenue, beating estimates. Stifel raised its target to $232, while UBS increased to $201, both noting strong smoke-free product growth.

investing.comNov 10

$BTIMed

JPMorgan reinstates British American Tobacco stock coverage with overweight rating

JPMorgan reinstated coverage on British American Tobacco (BTI) with an overweight rating and a GBP53.00 price target. The firm cited strong growth prospects and attractive valuation, expecting 3-5% like-for-like growth in 2027. Goldman Sachs also upgraded BTI to Buy, noting a clear growth inflection story. The stock trades at a P/E ratio of 15.4 and offers a 5.5% dividend yield.

investing.comNov 10

$ACBHighAI 9/10

Organigram Tables C$561m Aurora Bid, Blowing Curaleaf Out of the Water

Organigram offered C$7.80 per share (C$561m total) for Aurora Cannabis, topping Curaleaf's bid. Aurora's board recommends accepting. Organigram's offer includes cash and shares, backed by BAT. Deal needs shareholder and regulatory approvals, expected to close in January 2027. Combined entity would be a top Canadian cannabis company with global operations.

businessofcannabis.comNov 4

$BTIHigh

Goldman upgrades BAT on clearer path to sustained revenue growth

Goldman Sachs upgraded British American Tobacco (BAT) to 'buy' from 'neutral', raising its price target to 5,600 pence. The firm expects 4% organic sales growth in 2027-2028, driven by resilient combustible sales and New Categories growth. BAT trades at 12 times expected 2027 earnings, with a dividend yield near 6%. Goldman forecasts 5%-6% medium-term operating profit growth and 9% average EPS growth over five years, citing Velo Max and Vuse vapour volume growth as key drivers.

investing.comNov 2